Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of SC vs IV Efgartigimod in Healthy Males
NCT03334084Phase 1Completed
- Sponsor
- argenx
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG), immune thrombocytopenia (ITP) and pemphigus vulgaris (PV), sponsored by argenx. Started Oct 2017; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)immune thrombocytopenia (ITP)pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT03334084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334084.